4881Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time

Abstract

Background: In EMPA-REG OUTCOME, empagliflozin given in addition to standard of care significantly reduced the risk of cardiovascular (CV) (HR 0.62 [95% CI 0.49, 0.77]) and all-cause (0.68 [0.57, 0.82]) mortality vs placebo in patients with type 2 diabetes and established CV disease. We investigated the effects of controlling blood pressure (BP), low density lipoprotein cholesterol (LDL-C) and HbA1c on the treatment difference in mortality.Methods: Patients were randomised to empagliflozin 10 mg, empagliflozin 25 mg, or placebo. CV and all-cause mortality were assessed in the pooled empagliflozin group vs placebo adjusting for control of BP, LDL-C and HbA1c at baseline and during the study as time-dependent covariates. Control was defined as systolic BP <140 mmHg and diastolic BP <90 mmHg, LDL-C <100 mg/dL, and HbA1c <7.5%.